Synthesis of 7- and 10-spermine conjugates of paclitaxel and 10-deacetyl-paclitaxel as potential prodrugs

Tetrahedron Letters

Volumn 47, Issue 16, 2006, Pages 2667-2670

  Battaglia, Arturo ^a   Guerrini, Andrea ^a   Baldelli, Eleonora ^b   Fontana, Gabriele ^b   Varchi, Greta ^a   Samorì, Cristian ^a   Bombardelli, Ezio ^b  

^a CNR   (Italy)

^b INDENA S P A   (Italy)

Author keywords

Antitumor; Paclitaxel; Prodrug conjugates; Spermine

Indexed keywords

10 DEACETYL PACLITAXEL; PACLITAXEL; PACLITAXEL DERIVATIVE; PRODRUG; SPERMINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CHEMICAL MODIFICATION; CONJUGATE; CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; TUMOR CELL LINE;

EID: 33644981818     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2006.02.108     Document Type: Article

References (43)

1. K.C. Nicolaou, W.-M. Dai, and R.K. Guy Angew. Chem., Int. Ed. Engl. 33 1994 15 44
2. A.W. Menzin, S.A. King, J.K. Aikins, J.J. Mikuta, and S.C. Rubin Cancer. Gynecol. Oncol. 54 1994 103
3. E.K. Rowinski Annu. Rev. Med. 48 1997 353 374
4. R.V.J. Chari Adv. Drug Delivery Rev. 31 1998 89 104
5. See for example: R.B. Greenwald, C.W. Gilbert, A. Pendri, C.D. Conover, J. Xia, and A. Martinez J. Med. Chem. 39 1996 424 431
6. M. Ceruti, P. Crosasso, P. Brusa, S. Arpicco, F. Dosio, and L. Cattel J. Controlled Release 63 2000 141 153
7. Y. Hayashi, M. Skwarczynski, Y. Hamada, Y. Sohma, T. Kimura, and Y. Kiso J. Med. Chem. 46 2003 3782 3784
8. M.O. Bradley, N.L. Webb, F.H. Anthony, P. Devanesan, P.A. Witman, S. Hemamalini, M.C. Chander, S.D. Baker, L.F. He, S.B. Horwitz, and C.S. Swindell Clin. Cancer Res. 7 2001 3229 3238
9. These enzymes include the thiol protease Cathepsin B, metalloproteinases such as collagenases and stromelysins, and serine proteases like plasminogen activator and plasmin. See: J. Mai, D.M. Waisman, and B.F. Sloane Biochim. Biophys. Acta 1477 2000 215 230
10. A. Davidson, A.H. Drummond, W.A. Galloway, and M. Whittaker Chem. Ind. 1997 258 261
11. P.A. Andreasen, R. Egelund, and H.H. Petersen Cell. Mol. Life Sci. 57 2000 25 40
12. F.M.H. De Groot, L.W.A. Van Berkom, and H.W. Scheeren J. Med. Chem. 43 2000 3093 3102
13. V. Guillemard, and H.U. Saragovi Cancer Res. 61 2001 694 699
14. J. Jaime, and M. Page Anticancer Res. 21 2001 1119 1128
15. I. Ojima, X. Geng, X. Wu, C. Qu, C.P. Borella, H. Xie, S.D. Wilhelm, B.A. Leece, L.M. Bartle, V.S. Goldmacher, and R.V.J. Chari J. Med. Chem. 45 2002 5620 5623
16. S.S. Cohen A Guide to the Polyamines 1998 Oxford University Press Oxford
17. C.W. Tabor, and H. Tabor Annu. Rev. Biochem. 53 1984 749 790
18. A.E. Pegg Cancer Res. 48 1988 759 774
19. I.S. Blagbrough, S. Carrington, and A.J. Geall Pharm. Sci. 3 1997 223 233
20. K. Igarashi, and K. Kashiwagi Biochem. Biophys. Res. 271 2000 559 564
21. M. Yoshida, K. Kashiwagi, A. Shigemasa, S. Taniguchi, K. Kaneyoshi Yamamoto, H. Makinoshima, A. Akira Ishihama, and K. Igarashi J. Biol. Chem. 279 2004 46008 46013
22. See for example: K. Ito, K. Kashiwagi, S. Watanabe, T. Kameji, S. Hayashi, and K. Igarashi J. Biol. Chem. 265 1990 13036 13041
23. K. Kashiwagi, Y. Yamaguchi, Y. Sakai, H. Kobayashi, and K. Igarashi J. Biol. Chem. 265 1990 8387 8391
24. Only recent results reveal a physiological function of TATA-binding protein-associated factor 7 (TAF7) as a regulator for mammalian polyamine transport. See: J. Junichi Fukuchi, R.A. Hiipakka, J.M. Kokontis, K. Nishimura, K. Igarashi, and S. Liao J. Biol. Chem. 279 2004 29921 29929 and references cited therein
25. D.G. Vassylyev, H. Tomitori, K. Kashiwagi, K. Morikawa, and K. Igarashi J. Biol. Chem. 273 1998 17604 17609
26. R.A. Gardner, J.-G. Delcros, F. Konate, F. Breitbeil III, B. Martin, M. Sigman, M. Huang, and O. Phanstiel J. Med. Chem. 47 2004 6055 6069
27. M.R. Burns, C.L. Carlson, S.M. Vanderwerf, J.R. Ziemer, R.S. Weeks, F. Cai, H.K. Webb, and G.F. Graminski J. Med. Chem. 44 2001 3632 3644
28. A.Q. Siddiqui, L. Merson-Davies, and P.M. Cullis J. Chem. Soc., Perkin Trans. 1 1999 3243 3252
29. A. Jakobs, J. Bernadou, and B. Meunier J. Org. Chem. 62 1997 3505 3510
30. H. Rauter, R. Di Domenico, E. Menta, O. Oliva, Y. Qu, and N. Farrell Inorg. Chem. 36 1997 3919 3927
31. P. Amo-Ochoa, V.M. González, J.M. Pérez, J.R. Masaguer, C. Alonso, and C. Navarro-Ranninger J. Inorg. Biochem. 64 1996 287 299
32. F.M.H. De Groot, L.W.A. Van Berkom, and H.W. Scheeren J. Med. Chem. 43 2000 3093 3102
33. T.J. Altstadt, C.R. Fairchild, J. Golik, A.K. Johnston, J.F. Kadow, F.Y. Lee, B.H. Long, W.C. Rose, D.M. Vyas, H. Wong, M.-J. Wu, and M.D. Wittman J. Med. Chem. 44 2001 4577 4583
34. A. Datta, M. Hepperle, and G.I. Georg J. Org. Chem. 60 1995 761 776
35. P.G. Grothaus, T.J.G. Raybould, G.S. Bignami, C.B. Lazo, and J.B. Byrnes J. Immunol. Methods 158 1993 5 15
36. A.P. Neal, and I.S. Blagbrough Abs. Pap. Am. Chem. Soc. 224 2002 161-MEDI, Part 2
37. I.S. Blagbrough, A.J. Geall, and A.P. Neal Abs. Pap. Am. Chem. Soc. 224 2002 215-MEDI, part 2
38. I.S. Blagbrough, and A.J. Geall Tetrahedron Lett. 39 1998 439 442
39. +.
40. +.
41. I. Ojima, I. Fenoglio, Y.H. Park, P. Pera, and R.J. Bernacki Bioorg. Med. Chem. Lett. 37 1994 1408
42. As an example, the carboxylesterases metabolize the carbamate prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11; irinotecan) to its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), a potent topoisomerase I inhibitor. See: S.P. Sanghani, S.K. Quinney, T.B. Fredenburg, W.I. Davis, D.J. Murry, and W.F. Bosron Drug Metab. Dispos. 32 2004 505 511
43. J.G. Slatter, P. Su, J.P. Sams, L.J. Schaaf, and L.C. Wienkers Drug Metab. Dispos. 25 1997 1157 1164